TR200000349T2 - Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı. - Google Patents

Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı.

Info

Publication number
TR200000349T2
TR200000349T2 TR2000/00349T TR200000349T TR200000349T2 TR 200000349 T2 TR200000349 T2 TR 200000349T2 TR 2000/00349 T TR2000/00349 T TR 2000/00349T TR 200000349 T TR200000349 T TR 200000349T TR 200000349 T2 TR200000349 T2 TR 200000349T2
Authority
TR
Turkey
Prior art keywords
physiologically acceptable
complexes
salts
acceptable vanadium
vanadium compositions
Prior art date
Application number
TR2000/00349T
Other languages
English (en)
Inventor
Ghosal Gho Conradus
Original Assignee
Gho'st Holding B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gho'st Holding B.V. filed Critical Gho'st Holding B.V.
Publication of TR200000349T2 publication Critical patent/TR200000349T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Çevre dokudaki bir travmatik olay sonucu olusan, doku primer zedelenmesinin yol açtigi doku sekonder zedelenmesinin profilaktik tedavisi için farmasötik bir terkibin hazirlanmasinda aktif komponent olarak, fizyolojik olarak kabul edilebilir bir vanadyum bilesiminin, tuzunun veya kompleksinin kullanimi.
TR2000/00349T 1997-07-29 1998-07-29 Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı. TR200000349T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Publications (1)

Publication Number Publication Date
TR200000349T2 true TR200000349T2 (tr) 2000-09-21

Family

ID=19765422

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00349T TR200000349T2 (tr) 1997-07-29 1998-07-29 Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı.

Country Status (22)

Country Link
US (2) US6579540B1 (tr)
EP (1) EP1001792B1 (tr)
JP (1) JP2001511454A (tr)
CN (1) CN1104244C (tr)
AT (1) ATE253373T1 (tr)
AU (1) AU738701B2 (tr)
BR (1) BR9811298A (tr)
CA (1) CA2298645C (tr)
CZ (1) CZ299716B6 (tr)
DE (1) DE69819514T2 (tr)
DK (1) DK1001792T3 (tr)
EA (1) EA002574B1 (tr)
ES (1) ES2207851T3 (tr)
ID (1) ID24870A (tr)
IL (2) IL134259A0 (tr)
NL (1) NL1006681C2 (tr)
NO (1) NO20000446L (tr)
NZ (1) NZ502613A (tr)
PL (1) PL338415A1 (tr)
PT (1) PT1001792E (tr)
TR (1) TR200000349T2 (tr)
WO (1) WO1999006056A1 (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
AU1898700A (en) * 1999-12-20 2001-07-03 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and NA+/H+ exchange inhibitor
WO2003041703A2 (en) * 2001-11-16 2003-05-22 Gho Holding B.V. Use of a flavonoid for the treatment of burns
WO2008092935A2 (en) 2007-01-31 2008-08-07 Basf Plant Science Gmbh Plants having enhanced yield-related traits and/or increased abiotic stress resistance, and a method for making the same
EP2228386B1 (en) 2007-05-03 2015-03-18 BASF Plant Science GmbH Plants having enhanced yield-related traits and a method for making the same
EP2173884B1 (en) 2007-07-20 2013-09-18 BASF Plant Science GmbH Plants having increased yield-related traits and a method for making the same
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
AU2008320931B2 (en) 2007-10-29 2014-09-25 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
BRPI0912244A2 (pt) 2008-05-05 2016-10-11 Basf Plant Science Gmbh método para intensificar as características relacionadas com o rendimento em plantas em relação às plantas de controle, constructo, uso do mesmo, planta, parte de planta ou célula de planta, método para a produção de uma planta transgênica, planta transgênica, partes colhíveis de uma planta, produtos, e, uso de um ácido nucleico.
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
BR112012017535A2 (pt) 2010-01-15 2019-09-24 Of Medicine And Dentistry Of New Jersey University uso de compostos de vanádio para cicatrização de osso
EP2648718B1 (en) 2010-12-10 2019-05-08 Rutgers, the State University of New Jersey Implantable devices coated with insulin-mimetic agent composites and methods thereof
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
BR112013022907A2 (pt) * 2011-03-07 2016-09-13 Cfm Pharma Holding Bv composição farmacêutica
US9931348B2 (en) * 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012563A1 (en) * 1989-04-24 1990-11-01 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
FR2729957B1 (fr) * 1995-01-31 1997-12-05 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant.
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Also Published As

Publication number Publication date
PT1001792E (pt) 2004-03-31
EP1001792B1 (en) 2003-11-05
NO20000446D0 (no) 2000-01-28
IL134259A0 (en) 2001-04-30
EA002574B1 (ru) 2002-06-27
IL134259A (en) 2010-02-17
CA2298645C (en) 2004-05-18
WO1999006056A1 (en) 1999-02-11
BR9811298A (pt) 2000-08-29
EP1001792A1 (en) 2000-05-24
DK1001792T3 (da) 2004-01-19
AU8650598A (en) 1999-02-22
PL338415A1 (en) 2000-11-06
NZ502613A (en) 2001-08-31
AU738701B2 (en) 2001-09-27
US6579540B1 (en) 2003-06-17
NO20000446L (no) 2000-03-24
ATE253373T1 (de) 2003-11-15
ES2207851T3 (es) 2004-06-01
EA200000176A1 (ru) 2000-10-30
DE69819514T2 (de) 2004-09-23
ID24870A (id) 2000-08-31
CZ299716B6 (cs) 2008-10-29
CN1270525A (zh) 2000-10-18
DE69819514D1 (de) 2003-12-11
CA2298645A1 (en) 1999-02-11
CN1104244C (zh) 2003-04-02
US20030211170A1 (en) 2003-11-13
NL1006681C2 (nl) 1999-02-08
JP2001511454A (ja) 2001-08-14
CZ2000326A3 (cs) 2000-07-12

Similar Documents

Publication Publication Date Title
NO20000446L (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, - salter og -komplekser
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
ZA9711607B (en) Novel cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
WO1995031985A3 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
ATE252081T1 (de) Neue hiv-protease-inhibitoren
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
SE9802208D0 (sv) Novel compounds
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
BR0013009A (pt) Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos
EP0970700A3 (en) Gallium containing medicaments for enhancing wound healing and tissue repair
SE9802209D0 (sv) Novel compounds
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
GEP20043231B (en) Resorcinol Composition
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih
BR0115911A (pt) Uso de pirazolo[4,3-d]pirimidinas
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler